Titre : Interleukine-9

Interleukine-9 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Data Collection
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-9 : Questions médicales les plus fréquentes", "headline": "Interleukine-9 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-9 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-04", "dateModified": "2025-03-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-9" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-9", "alternateName": "Interleukin-9", "code": { "@type": "MedicalCode", "code": "D016906", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Sushmita Chakraborty", "url": "https://questionsmedicales.fr/author/Sushmita%20Chakraborty", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Dipendra Kumar Mitra", "url": "https://questionsmedicales.fr/author/Dipendra%20Kumar%20Mitra", "affiliation": { "@type": "Organization", "name": "Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi 110029, India." } }, { "@type": "Person", "name": "Mattia Matasci", "url": "https://questionsmedicales.fr/author/Mattia%20Matasci", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Dario Neri", "url": "https://questionsmedicales.fr/author/Dario%20Neri", "affiliation": { "@type": "Organization", "name": "Philochem AG, CH-8112 Otelfingen, Switzerland." } }, { "@type": "Person", "name": "Katharina F Kubatzky", "url": "https://questionsmedicales.fr/author/Katharina%20F%20Kubatzky", "affiliation": { "@type": "Organization", "name": "Department of Infectious Diseases, Medical Microbiology and Hygiene, Heidelberg University, Heidelberg, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Data collection on rare bone and mineral conditions in Europe: The landscape of registries and databases.", "datePublished": "2023-10-30", "url": "https://questionsmedicales.fr/article/38832910", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejmg.2023.104868" } }, { "@type": "ScholarlyArticle", "name": "Ethical Considerations for Artificial Intelligence in Medical Imaging: Data Collection, Development, and Evaluation.", "datePublished": "2023-12-01", "url": "https://questionsmedicales.fr/article/37827839", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2967/jnumed.123.266080" } }, { "@type": "ScholarlyArticle", "name": "Exploring the perspectives of selectors and collecters of trial outcome data: an international qualitative study.", "datePublished": "2023-10-11", "url": "https://questionsmedicales.fr/article/37821867", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12874-023-02054-9" } }, { "@type": "ScholarlyArticle", "name": "Do privacy assurances work? a study of truthfulness in healthcare history data collection.", "datePublished": "2022-11-09", "url": "https://questionsmedicales.fr/article/36350919", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0276442" } }, { "@type": "ScholarlyArticle", "name": "Single-Particle Cryo-EM Data Collection with Stage Tilt using Leginon.", "datePublished": "2022-07-01", "url": "https://questionsmedicales.fr/article/35848829", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3791/64136" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-9", "item": "https://questionsmedicales.fr/mesh/D016906" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-9 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-9", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-9", "description": "Comment mesurer l'interleukine-9 ?\nQuels tests sont utilisés pour le diagnostic ?\nL'IL-9 est-elle liée à des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-9 ?\nL'IL-9 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-9", "description": "Quels symptômes sont liés à l'IL-9 ?\nL'IL-9 provoque-t-elle des symptômes respiratoires ?\nY a-t-il des symptômes cutanés associés ?\nL'IL-9 est-elle liée à des symptômes gastro-intestinaux ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-9", "description": "Comment prévenir les maladies liées à l'IL-9 ?\nY a-t-il des vaccins pour l'IL-9 ?\nL'éducation des patients est-elle importante ?\nLes changements alimentaires peuvent-ils aider ?\nLe contrôle de l'environnement est-il crucial ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-9", "description": "Comment traiter les niveaux élevés d'IL-9 ?\nY a-t-il des thérapies ciblées pour l'IL-9 ?\nLes corticostéroïdes affectent-ils l'IL-9 ?\nQuels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?\nL'immunothérapie aide-t-elle avec l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-9", "description": "Quelles complications peuvent survenir avec l'IL-9 ?\nL'IL-9 peut-elle aggraver d'autres maladies ?\nY a-t-il des risques de surinfection ?\nDes complications pulmonaires sont-elles possibles ?\nL'IL-9 est-elle liée à des troubles cardiovasculaires ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-9", "description": "Quels sont les facteurs de risque pour l'IL-9 ?\nL'exposition à la pollution augmente-t-elle le risque ?\nLe tabagisme influence-t-il l'IL-9 ?\nLes infections respiratoires sont-elles un facteur ?\nLe stress a-t-il un impact sur l'IL-9 ?", "url": "https://questionsmedicales.fr/mesh/D016906?mesh_terms=Data+Collection&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'interleukine-9 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 peut être mesurée par des tests ELISA dans le sérum ou les fluides biologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses de cytokines sont utilisés pour évaluer l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est associée à des maladies comme l'asthme et certaines allergies." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-9 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-9 est souvent mesurée avec d'autres cytokines comme l'IL-4 et l'IL-5." } }, { "@type": "Question", "name": "L'IL-9 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-9 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'IL-9 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des réactions allergiques, de l'asthme et des inflammations." } }, { "@type": "Question", "name": "L'IL-9 provoque-t-elle des symptômes respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 est impliquée dans l'hyperréactivité bronchique et l'asthme." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cutanés associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées peuvent survenir dans des conditions allergiques liées à l'IL-9." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des symptômes gastro-intestinaux ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut être impliquée dans des troubles gastro-intestinaux allergiques." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des difficultés respiratoires, des éruptions cutanées et des démangeaisons." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à l'IL-9 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les allergènes et adopter un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Y a-t-il des vaccins pour l'IL-9 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour cibler l'IL-9." } }, { "@type": "Question", "name": "L'éducation des patients est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, informer les patients sur les déclencheurs allergiques est essentiel pour la prévention." } }, { "@type": "Question", "name": "Les changements alimentaires peuvent-ils aider ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut aider à réduire l'inflammation et les symptômes." } }, { "@type": "Question", "name": "Le contrôle de l'environnement est-il crucial ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, réduire l'exposition aux allergènes environnementaux est essentiel pour la prévention." } }, { "@type": "Question", "name": "Comment traiter les niveaux élevés d'IL-9 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements anti-inflammatoires et des antihistaminiques peuvent être utilisés." } }, { "@type": "Question", "name": "Y a-t-il des thérapies ciblées pour l'IL-9 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps monoclonaux ciblant l'IL-9 sont en développement pour traiter l'asthme." } }, { "@type": "Question", "name": "Les corticostéroïdes affectent-ils l'IL-9 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les corticostéroïdes peuvent réduire les niveaux d'IL-9 et l'inflammation associée." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour l'asthme lié à l'IL-9 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme les bronchodilatateurs et les corticostéroïdes sont couramment prescrits." } }, { "@type": "Question", "name": "L'immunothérapie aide-t-elle avec l'IL-9 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'immunothérapie peut aider à moduler la réponse immunitaire liée à l'IL-9." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec l'IL-9 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des exacerbations d'asthme et des réactions allergiques sévères." } }, { "@type": "Question", "name": "L'IL-9 peut-elle aggraver d'autres maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut exacerber des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des risques de surinfection ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients avec des niveaux élevés d'IL-9 peuvent être à risque de surinfections." } }, { "@type": "Question", "name": "Des complications pulmonaires sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-9 peut contribuer à des complications pulmonaires comme la fibrose." } }, { "@type": "Question", "name": "L'IL-9 est-elle liée à des troubles cardiovasculaires ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'IL-9 et des troubles cardiovasculaires, mais c'est encore à étudier." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour l'IL-9 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux d'allergies et d'asthme augmentent le risque d'IL-9 élevée." } }, { "@type": "Question", "name": "L'exposition à la pollution augmente-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la pollution de l'air est un facteur de risque connu pour les maladies liées à l'IL-9." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il l'IL-9 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-9 et aggraver les symptômes respiratoires." } }, { "@type": "Question", "name": "Les infections respiratoires sont-elles un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les infections respiratoires peuvent déclencher une réponse immunitaire impliquant l'IL-9." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur l'IL-9 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les symptômes et augmenter les niveaux d'IL-9." } } ] } ] }

Sources (10000 au total)

Data collection on rare bone and mineral conditions in Europe: The landscape of registries and databases.

knowledge on the natural history of rare diseases is necessary to improve outcomes. Disease registries may play a key role in covering these unmet needs in the rare bone and mineral community.... to map existing bone and mineral conditions registries in Europe and their characteristics.... online survey about the use of registries/databases and their characteristics. This survey was disseminated among members of the European Reference Network on Rare Bone Diseases (ERN BOND) and non-ERN... sixty-three responses from health care providers (HCPs) and 10 responses from patient groups (PGs) were collected. The response rate for ERN BOND members was 55%. Of 63 HCPs, 37 declared using a regis... There is a need for developing a common high-quality platform for registering rare bone and mineral conditions....

Exploring the perspectives of selectors and collecters of trial outcome data: an international qualitative study.

Selecting and collecting data to support appropriate primary and secondary outcomes is a critical step in designing trials that can change clinical practice. In this study, we aimed to investigate who... One-with-one semi-structured interviews, supported by a topic guide to ensure coverage of key content. The Framework approach was used for thematic analysis of data, and themes were linked through con... We identified three descriptive themes encompassing the process of primary and secondary outcome selection, collection, and the publication of outcome data. Within these themes, participants raised is... People involved in the design and conduct of trials fail to connect decisions around outcome selection with data collection workload. Publication of outcome data and effective dissemination of trial r...

Use of the BACtrack Skyn alcohol biosensor: Practical applications for data collection and analysis.

Alcohol biosensors, including the BACtrack Skyn, provide an objective and passive method of continuously assessing alcohol consumption in the natural environment. Despite the many strengths of the Sky... Procedures from several laboratory and field-based pilot studies are presented to demonstrate practical recommendations for Skyn use. Data from a pilot study including a 7-day ecological momentary ass... To address challenges in the collection and processing of data from the BACtrack Skyn alcohol biosensor, researchers should identify goals in advance of data collection to anticipate the processing ne...

Managing the elephant in the room: responding to COVID-19's impact on data collection.

The global COVID-19 pandemic has affected data collection for many researchers, in particular research that involves face-to-face interviews.... To share learning about the challenges encountered when face-to-face interviews could not continue as planned in a study and how to adapt data collection so that it can continue despite severe disrupt... This article examines the considerations and actions taken by the authors to ensure the continuity of data collection. The research aimed to use narrative inquiry to understand the experiences of sign... Adapting data collection is valuable in ensuring the continuity of research. Careful consideration and planning are required to ensure the research remains robust and ethically sound.... Adapting data collection methods can allow for greater flexibility when participants cannot attend face-to-face interviews....

Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection.

The demand and consumption of immunoglobulins (IgGs) are growing, and there are many difficulties in obtaining supplies. The aim of the study was to analyze the evolution of IgG consumption and cost o... We performed a retrospective longitudinal study including patients of all public health systems in Catalonia. First, we analyzed data on consumption and cost of IgGs during a period between 1 January,... Overall, in terms of population, the consumption of IgGs (g/1,000 inhabitants) increased from 40.4 in 2010 to 94.6 in 2021. The mean cost per patient increased from €10,930 in 2010 to €15,595 in 2021.... The annual consumption and cost of IgGs have grown steadily over the last decade in our regional public health system. After implementing a set of regional measures, the annual consumption of IgGs per...